Inspired by Nature.
Empowered by Technology.
Committed to Life.
Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
News & Press
NAMina Bio is building a translational ecosystem dedicated to advancing human-relevant models, New Approach Methodologies, and decision-ready platforms for biomedical innovation.
This page brings together NAMina Bio’s latest news, media mentions, scientific milestones, partnership updates, events, and thought leadership as we continue to connect advanced in vitro technologies, translational biology, and strategic collaboration across the life sciences ecosystem.
Excited to share that NAMina Bio is entering a new activation phase.
Our goal is to build a capital-efficient translational architecture platform that integrates human-relevant models, 3D bioprinting, organoids, organ-on-chip systems, multi-omics, and AI-driven analytics into decision-ready workflows for drug development.
The next step is focused on BioLabs-based launch planning, modular 3D bioprinting and advanced in vitro modeling capabilities, and partner-enabled execution across translational model systems.What makes this phase important is not only the technology itself, but the operating model: a lean integration layer that can design, orchestrate, and connect specialized platforms into structured programs for biotech and pharma.
NAMina Bio is now opening strategic conversations with aligned investors, technology partners, and translational research collaborators who share the vision of building more predictive, human-relevant drug development infrastructure.
From biology, to data, to better decisions.
New York, 5/10/2026
Who talks about us...
NAMina Bio Receives Best Score in First Round at the 2026 Medical Innovation Olympics
NAMina Bio is proud to share that Founder & CEO Paola Dama, participated in the 2026 Medical Innovation Olympics at Rockefeller Center in New York City and received the best score in the first round.
The event brought together healthcare innovators, clinicians, investors, entrepreneurs, and leaders across medicine, health, AI, and translational science to advance ideas focused on improving access, quality, and continuity of care.
During the pitch session, NAMina Bio presented its vision for building the integration layer for human-relevant translational evidence, helping fragmented New Approach Methodology technologies become standardised, comparable, and decision-ready.
For NAMina Bio, participation in the Medical Innovation Olympics represented an important opportunity to share its mission with a broader healthcare innovation community and to contribute to the growing conversation around human-relevant, AI-supported, and non-animal evidence systems in translational research and drug development.
NAMina Bio is grateful to Tim Mikhelashvili, the promoter of the event, Shota Bagaturia and the Medical Innovation Olympics team for their hospitality, for creating a meaningful platform for healthcare champions, and for fostering valuable conversations and connections across the innovation ecosystem.
This recognition marks an encouraging milestone for NAMina Bio as the company continues to build toward the next generation of human-relevant translational evidence.
